Quick Answer
CYTOKINETICS INC reported Total Revenue of $88.04 million for fiscal year 2025.
CYTOKINETICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $88.04M +376.6% |
$18.47M +145.3% |
$7.53M -92.0% |
$94.59M +34.3% |
$70.43M +26.2% |
$55.83M +107.8% |
| Revenue (ASC 606) | $88.04M +376.6% |
$18.47M +145.3% |
$7.53M -92.0% |
$94.59M +34.3% |
$70.43M +26.2% |
$55.83M +107.8% |
| Net Income | -$784.96M -33.2% |
-$589.53M -12.0% |
-$526.24M -35.3% |
-$388.95M -80.6% |
-$215.31M -69.2% |
-$127.29M -4.6% |
| Diluted EPS | -$6.54 -24.3% |
-$5.26 +3.5% |
-$5.45 -25.9% |
-$4.33 -54.6% |
-$2.80 -42.1% |
-$1.97 |
| Total Assets | $1.42B +1.6% |
$1.40B +70.0% |
$824.32M -18.8% |
$1.01B +20.6% |
$841.32M +57.6% |
$533.80M +84.2% |
| Cash and Equivalents | $122.52M +29.2% |
$94.86M -16.1% |
$113.02M +72.3% |
$65.58M -41.8% |
$112.67M +35.8% |
$82.98M +127.8% |
| Long-Term Debt | $246.38M +164.3% |
$93.23M +59.7% |
$58.38M -8.5% |
$63.81M +34.7% |
$47.37M +2.5% |
$46.21M +2.6% |
| Stockholders Equity | -$659.62M -387.3% |
-$135.37M +65.0% |
-$386.32M -258.0% |
-$107.90M -144.2% |
$243.86M +115.1% |
$113.38M +1136.7% |
| R&D Expense | $416.03M +22.6% |
$339.41M +2.8% |
$330.12M +37.1% |
$240.81M +50.6% |
$159.94M +65.0% |
$96.95M +12.6% |
| Operating Income | -$612.26M -14.2% |
-$536.25M -8.1% |
-$496.20M -53.1% |
-$324.20M -74.0% |
-$186.31M -98.3% |
-$93.94M +5.0% |
| Shares Outstanding | 122.94M +4.0% |
118.21M +16.3% |
101.64M +7.2% |
94.83M +11.8% |
84.80M +19.4% |
71.02M +20.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.94M | +318.1% | -97.1% |
| Revenue (ASC 606) | September 30, 2025 | $1.94M | +318.1% | -97.1% |
| Net Income | September 30, 2025 | -$306.18M | -90.7% | -127.9% |
| Diluted EPS | September 30, 2025 | -$2.55 | -87.5% | -127.7% |
| Total Assets | September 30, 2025 | $1.44B | +0.0% | +17.2% |
| Cash and Equivalents | September 30, 2025 | $225.47M | +380.9% | +200.9% |
| Long-Term Debt | September 30, 2025 | $158.75M | +70.7% | -0.2% |
| Stockholders Equity | September 30, 2025 | -$521.12M | -3646.1% | -41.3% |
| R&D Expense | September 30, 2025 | $99.23M | +17.3% | -11.8% |
| Operating Income | September 30, 2025 | -$166.75M | -18.4% | -49.5% |
| Shares Outstanding | September 30, 2017 | 53.86M | +32.9% | +0.8% |
- CYTOKINETICS INC reported Total Revenue of $88.04 million for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +376.6% in Total Revenue compared to the prior fiscal year.
- CYTOKINETICS INC reported Revenue (ASC 606) of $88.04 million for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +376.6% in Revenue (ASC 606) compared to the prior fiscal year.
- CYTOKINETICS INC reported Net Income of -$784.96 million for fiscal year 2025.
- CYTOKINETICS INC showed a decrease of -33.2% in Net Income compared to the prior fiscal year.
- CYTOKINETICS INC reported Diluted EPS of $6.54 per share (loss) for fiscal year 2025.
- CYTOKINETICS INC showed a decrease of -24.3% in Diluted EPS compared to the prior fiscal year.
- CYTOKINETICS INC reported Total Assets of $1.42 billion for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +1.6% in Total Assets compared to the prior fiscal year.
- CYTOKINETICS INC reported Cash and Equivalents of $122.52 million for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +29.2% in Cash and Equivalents compared to the prior fiscal year.
- CYTOKINETICS INC reported Long-Term Debt of $246.38 million for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +164.3% in Long-Term Debt compared to the prior fiscal year.
- CYTOKINETICS INC reported Stockholders Equity of -$659.62 million for fiscal year 2025.
- CYTOKINETICS INC showed a decrease of -387.3% in Stockholders Equity compared to the prior fiscal year.
- CYTOKINETICS INC reported R&D Expense of $416.03 million for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +22.6% in R&D Expense compared to the prior fiscal year.
- CYTOKINETICS INC reported Operating Income of -$612.26 million for fiscal year 2025.
- CYTOKINETICS INC showed a decrease of -14.2% in Operating Income compared to the prior fiscal year.
- CYTOKINETICS INC reported Shares Outstanding of 122.94 million shares for fiscal year 2025.
- CYTOKINETICS INC showed an increase of +4.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: